#ACRX #AERI #ONCE Three catalyst biotech to watch next week.


08-Oct-2017 14:48 PM



   One of the most common trading style for the biotech enthusisast our there is trade on the run up with catalyst. These three are the prime example and the stock has made a nice run. Traders and investors out there should be aware that stock will be halt during FDA day. Plan your trade accordingly. 

You can check our calendar to know the upcoming PDUFA/Adcomm,  Notable Earning Reports stockS. and MACRO events here

 Here are the three upcoming FDA decision this week for these three biotech.

1. #ACRX AcelRx Pharmaceutical Inc,:  Prescription Drug User Fee Act (PDUFA) goal date of October 12, 2017 was assigned. DSUVIA™ (sufentanil sublingual tablet, 30 mcg) for the treatment of patients experiencing moderate-to-severe acute pain in a medically supervised setting

2 #AERI Aerie Pharmaceuticals, Inc. FDA Advisory Committee Meeting for Rhopressa™ (netarsudil ophthalmic solution) 0.02%. Oct 13, 2017 

3. #ONCE Spark Therapeutics, Inc. FDA Adisory Committee Meeting, October 12, 2017


What are you opinions the stock move after the event?




08-Oct-2017 19:30 PM

Very helpful. Planning strangle on AERI, not so sure tho. ONCE have no option listings. ;D

Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.